CQUniversity
Browse
Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy.pdf (619.09 kB)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy

Download (619.09 kB)
journal contribution
posted on 2022-07-27, 03:10 authored by Alex Molassiotis, Hui Lin Cheng, Kwun To Leung, Yu Chung Li, Kam Hung Wong, Joseph Siu Kie Au, Raghav Sundar, Alexandre Chan, Terrence Rong De Ng, Lorna KP Suen, Choi Wan Chan, Janelle Yorke, Violeta LopezVioleta Lopez
Background: Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN have been identified to date, but inconsistencies and methodological limitations exist in past research. Also, a limited number of potential risk factors has been investigated in the past. Aim: The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN. Methods: This analysis used the 6‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medication history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemotherapy with the neuropathy (motor/sensory) items of the NCI‐CTCAE scale and the WHO criterion for neuropathy. Data on symptom burden were also collected. Results: Data were available from 255 patients from three cancer centers in Hong Kong, Singapore, and UK. The use of different scales did not always identify the same predictor variables. Key risk factors in multivariate regression models included older age (highest OR = 1.08, p < 0.01 with the WHO scale), chemotherapy (platinum‐based chemotherapy had OR = 0.20–0.27 in developing CIPN compared to taxane‐based chemotherapy), history of neuropathy (for motor CIPN only, OR = 8.36, p < 0.01), symptom burden (OR = 1.06, p < 0.05), number of chemotherapy cycles received (OR = 1.19–1.24, p < 0.01), and alcohol intake (OR = 0.32, p < 0.05). In univariate analysis, the use of statins was implicated with CIPN (p = 0.03–0.04 with different assessments) and diabetes showed a trend (p = 0.09) in the development of CIPN.

History

Volume

9

Issue

6

Start Page

1

End Page

10

Number of Pages

10

eISSN

2162-3279

ISSN

2162-3279

Publisher

Wiley Open Access

Additional Rights

CC BY 4.0

Language

en

Peer Reviewed

  • Yes

Open Access

  • Yes

Acceptance Date

2019-04-24

External Author Affiliations

National University of Singapore; University of Manchester, UK; National University Health System, Singapore; The Hong Kong Polytechnic University; Queen Elisabeth Hospital, Hong Kong; Hong Kong Adventist Hospital

Era Eligible

  • Yes

Journal

Brain and Behavior

Article Number

e01312

Usage metrics

    CQUniversity

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC